Cancer Therapy

U.S. FDA approves IND application for phase II study of cancer drug Elacyt

Published in Cancer Weekly, October 11th, 2005

Clavis Pharma, a biopharmaceutical company focusing on the development of improved cancer therapeutics, announced that the U.S. Food & Drug Administration (FDA) has approved the investigational new drug application (IND) for the clinical development of its lead drug candidate, Elacyt, for the treatment of cancer.

Elacyt is Clavis Pharma's most advanced drug candidate in development for solid tumors and leukemia. The company has successfully finalized a phase I study in Europe where the product's safety profile was established and clinical benefit (defined as tumor response or stable disease) was reported in 41% of the patients, all suffering from advanced-stage solid...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-10-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry